About
Mirvie is a pioneering precision medicine company whose RNA platform delivers a personalized window into pregnancy health. At its core is the Encompass™ test — a non-invasive blood test that sequences RNA molecules produced by the baby, the placenta, and the mother. By analyzing tens of thousands of these biological signals with advanced machine learning models, the platform can predict life-threatening complications such as preeclampsia and spontaneous preterm birth months before they occur or symptoms appear. Traditional pregnancy monitoring often detects complications only after they arise, leaving little time for meaningful intervention. Mirvie's approach fundamentally changes this by identifying risk patterns in early pregnancy biology — including early in the first trimester — enabling both mothers and clinicians to take proactive, preventive action before a complication becomes a crisis. Clinically validated through landmark peer-reviewed studies published in Nature and the American Journal of Obstetrics and Gynecology, the platform has demonstrated the ability to identify approximately three-quarters of women who will later develop preeclampsia. Mirvie is headquartered in South San Francisco and continues to expand its clinical research to cover additional pregnancy complications. The platform is designed for OB-GYN practices, maternal-fetal medicine specialists, and health systems seeking to modernize prenatal care with AI-driven, biology-first insights. It is particularly valuable for high-risk pregnancies and improving outcomes for millions of mothers and babies worldwide.
Key Features
- RNA-Based Pregnancy Profiling: Analyzes tens of thousands of RNA messages from the baby, placenta, and mother from a single blood draw to reveal the unique biological state of each pregnancy.
- Early Complication Prediction: Predicts preeclampsia and preterm birth months before symptoms appear, with studies showing detection of ~75% of at-risk women early in pregnancy.
- Machine Learning Integration: Combines revolutionary RNA analysis with advanced ML models to identify risk signatures that are invisible to conventional prenatal screening.
- Encompass™ Test for Preeclampsia: A clinically validated, non-invasive blood test named to TIME's Best Inventions of 2025, designed to flag preeclampsia risk well before onset.
- Landmark Clinical Validation: Backed by peer-reviewed research published in Nature, Nature Communications, and the American Journal of Obstetrics and Gynecology.
Use Cases
- Early identification of women at risk for preeclampsia during routine first-trimester prenatal visits, enabling preventive care plans before symptoms emerge.
- Predicting spontaneous preterm birth risk so clinicians can take proactive measures to extend gestation and improve neonatal outcomes.
- Personalizing prenatal care protocols for high-risk pregnancies based on the unique RNA biology of each individual pregnancy.
- Supporting maternal-fetal medicine specialists with AI-driven diagnostic intelligence to reduce late-stage pregnancy crisis interventions.
- Advancing clinical research into the biological drivers of pregnancy complications to develop new standards of preventive obstetric care.
Pros
- Months-Early Detection: Identifies risk for serious complications like preeclampsia and preterm birth far earlier than traditional monitoring, enabling preventive intervention rather than crisis management.
- Clinically Validated Science: Supported by multiple landmark studies in top peer-reviewed journals, providing strong evidence for clinical adoption and patient trust.
- Non-Invasive and Simple: Requires only a standard blood draw, making it easy to integrate into routine prenatal care visits without additional patient burden.
- Personalized Biological Insights: Goes beyond population-level risk scores to reveal the underlying biology of each individual pregnancy, enabling truly personalized care.
Cons
- Limited Availability: As a specialized clinical diagnostic, Mirvie may not yet be accessible in all regions or health systems, limiting reach for some patients.
- Paid Clinical Service: As a proprietary diagnostic test, costs may not be covered by all insurance plans, creating potential access barriers for some patients.
- Narrow Current Scope: Currently focused primarily on preeclampsia and preterm birth prediction; coverage of other pregnancy complications is still under ongoing clinical research.
Frequently Asked Questions
What is the Mirvie Encompass™ test?
The Encompass™ test is Mirvie's flagship RNA-based blood test that analyzes tens of thousands of biological signals to predict pregnancy complications like preeclampsia and preterm birth months before symptoms appear.
How early in pregnancy can Mirvie detect risks?
Mirvie's platform can identify risk signals as early as the first trimester, well before symptoms of conditions like preeclampsia typically manifest in late pregnancy.
How accurate is Mirvie's preeclampsia prediction?
Clinical research published in Nature and Nature Communications shows the platform can identify approximately three-quarters (75%) of women who will later develop preeclampsia.
Who is Mirvie designed for?
Mirvie is designed for OB-GYN physicians, maternal-fetal medicine specialists, and health systems seeking to incorporate AI-driven, biology-first insights into prenatal care, particularly for high-risk patients.
Is the Mirvie platform peer-reviewed?
Yes. Mirvie's technology is backed by landmark research published in leading journals including Nature, Nature Communications, and the American Journal of Obstetrics and Gynecology.
